BIOLASE (NASDAQ:BIOL) Receives New Coverage from Analysts at StockNews.com
by Scott Moore · The Cerbat GemStockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the medical technology company’s stock.
BIOLASE Price Performance
Shares of BIOL opened at $0.14 on Wednesday. The company has a market capitalization of $4.61 million, a P/E ratio of 0.00 and a beta of 0.67. The company has a quick ratio of 0.68, a current ratio of 1.26 and a debt-to-equity ratio of 34.06. The firm has a 50 day moving average of $0.19 and a 200 day moving average of $0.92. BIOLASE has a twelve month low of $0.13 and a twelve month high of $47.10.
BIOLASE (NASDAQ:BIOL – Get Free Report) last announced its quarterly earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share for the quarter. The firm had revenue of $13.49 million for the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%.
Institutional Investors Weigh In On BIOLASE
A number of large investors have recently added to or reduced their stakes in the stock. State Street Corp grew its position in BIOLASE by 4.5% in the 1st quarter. State Street Corp now owns 436,076 shares of the medical technology company’s stock worth $154,000 after purchasing an additional 18,682 shares during the period. Renaissance Technologies LLC grew its position in shares of BIOLASE by 128.5% during the 4th quarter. Renaissance Technologies LLC now owns 43,059 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 24,211 shares during the period. Citadel Advisors LLC bought a new stake in shares of BIOLASE during the 2nd quarter valued at $118,000. Finally, Walleye Capital LLC bought a new stake in shares of BIOLASE during the 2nd quarter valued at $100,000. Institutional investors own 8.79% of the company’s stock.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.